Red Blood Cell Transfusions
Treatment for Thalassemias
Typical Dosage: 10-15 mL/kg packed red blood cells every 2-4 weeks
Effectiveness
90%
Safety Score
60%
Clinical Trials
24
Participants
1M
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
10-15 mL/kg packed red blood cells every 2-4 weeks
Time to Effect
immediate
Treatment Duration
lifetime
Evidence Quality
HIGHConfidence Score
100%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$20,000
Monitoring:$3,000
Side Effect Mgmt:$2,000
Total Annual:$25,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
10
Outcome-Based Costs
Cost per Responder
$25,000
Red Blood Cell Transfusions Outcomes
for Thalassemias
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+100%
Common Side Effects
Iron overload
+100%
Febrile non-hemolytic transfusion reaction
+2%
Allergic reaction
+3%
Alloimmunization
+15%
Transfusion-transmitted infections
+0.00005%
Active Clinical Trials
5 active trials recruiting for Red Blood Cell Transfusions in Thalassemias
Heterologous Cord Blood-Derived Red Blood Cell for Transfusion in Extremely Preterm Infants
NCT07502781NOT YET RECRUITINGNA
176 participants
INTERVENTIONAL
Barcelona, Spain
Started: Jan 1, 2027
A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.
NCT05567458ACTIVE NOT RECRUITINGPHASE2
94 participants
INTERVENTIONAL
Maoming, China +9 more
Started: Oct 17, 2022
Use of the Hemanext One® Hypoxic Red Blood Cell Storage System for Transfusion in Thalassemia Patients
NCT07055503ENROLLING BY INVITATION
30 participants
OBSERVATIONAL
Athens, Greece
Started: Nov 20, 2025
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
NCT04143724RECRUITINGPHASE2
99 participants
INTERVENTIONAL
Los Angeles, United States +25 more
Started: Nov 7, 2019
Transfusion-Related Changes in Oxidative Stress Biomarkers in Neonates
NCT07672275RECRUITING
170 participants
OBSERVATIONAL
Graz, Austria
Started: Dec 12, 2025
Completed Clinical Trials
12 completed trials for Red Blood Cell Transfusions in Thalassemias
Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients
NCT05255445COMPLETED
157 participants
OBSERVATIONAL
Oakland, United States +13 more
Started: Mar 16, 2022
Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
NCT01740531COMPLETEDPHASE3
86 participants
INTERVENTIONAL
Cagliari, Italy +2 more
Started: Dec 1, 2012
Red Blood Cells From Umbilical Cord for Transfusion of Preterm Infants
NCT05612919COMPLETEDNA
41 participants
INTERVENTIONAL
Barcelona, Spain
Started: Sep 13, 2023
Fresh Versus Old Red Blood Cells for Transfusion
NCT01319552COMPLETEDNA
14 participants
INTERVENTIONAL
New York, United States
Started: Dec 1, 2008
Impact of the Preparation Method of Red Cell Concentrates on Transfusion Indices in Thalassemic Patients
NCT03992001COMPLETEDPHASE4
55 participants
INTERVENTIONAL
Ferrara, Italy
Started: May 14, 2018
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
NCT04987489COMPLETEDPHASE2
53 participants
INTERVENTIONAL
Cerritos, United States +31 more
Started: Mar 28, 2022
Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients
NCT06146478COMPLETEDPHASE3
200 participants
INTERVENTIONAL
Peshawar, Pakistan
Started: Jan 25, 2022
Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients
NCT03877809COMPLETEDPHASE2
26 participants
INTERVENTIONAL
Ferrara, Italy +1 more
Started: Jun 27, 2019
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
NCT00235391COMPLETEDPHASE3
1.68K participants
INTERVENTIONAL
Little Rock, United States +140 more
Started: Oct 1, 2005
Vitamin E Supplementation for Children With Transfusion Dependent Beta Thalassemia on Different Iron Chelation Regimen
NCT06509581COMPLETEDNA
180 participants
INTERVENTIONAL
Cairo, Egypt
Started: Jul 5, 2021
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
NCT02604433COMPLETEDPHASE3
336 participants
INTERVENTIONAL
Los Angeles, United States +75 more
Started: May 2, 2016
A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia
NCT03342404COMPLETEDPHASE2
145 participants
INTERVENTIONAL
Los Angeles, United States +15 more
Started: Feb 5, 2018
Showing 20 of 26 total trials